First Targeted Therapy for CDKL5 Deficiency Disorder Approved in Europe

The European Medicines Agency (EMA) has granted final approval for Ztalmy (ganaxolone) from Marinus Pharmaceuticals (MRNS) as a treatment for individuals aged 2 to 17 years with CDKL5 Deficiency Disorder (CDD) who experience seizures. This approval marks a significant milestone as it represents the first targeted therapy for this rare genetic disorder to receive regulatory approval. Ztalmy is a positive allosteric modulator (PAM) that acts on the GABA_A receptor, a major inhibitory neurotransmitter in the brain, and has demonstrated a significant reduction in the frequency of difficult-to-treat seizures in patients who do not respond to existing anti-epileptic medications. This EMA approval follows the FDA approval in March 2022 and is expected to provide a new treatment option for approximately 10,000 patients in Europe.

Context of Global Commercial Partnership and Rights Reacquisition

Marinus initially entered into an exclusive licensing agreement with Orion Corporation in August 2021 to facilitate access to the European market. The agreement included an upfront payment of €25 million (approximately $30 million) and potential milestone payments of up to €97 million (approximately $115 million), totaling €122 million. However, in December 2024, the agreement was terminated by mutual consent. Orion decided to focus on oncology and pain management, leading to Marinus reacquiring full commercial rights to Ztalmy in Europe. As a result, Marinus will reimburse Orion €1.5 million in the first half of 2025 and will now independently or through a new partner, commercialize Ztalmy in Europe, marking a significant commercial turning point.

Clinical Value and Demonstrated Differentiated Therapeutic Efficacy

The key evidence supporting the EMA approval of Ztalmy comes from the positive efficacy and safety data demonstrated in the Phase 3 Marigold study. In this clinical trial, the Ztalmy treatment group showed a significant reduction in the average frequency of major motor seizures by 30.7% compared to the placebo group over a 28-day period. This represents a clinically meaningful difference compared to the 6.9% reduction observed in the control (placebo) group. Common adverse events included somnolence and pyrexia, but these were generally mild, indicating good tolerability and a favorable safety profile for long-term use.

Increasing Competition in the CDD Market and Market Outlook

The global CDKL5 Deficiency Disorder (CDD) treatment market is estimated at approximately $116.9 million in 2025 and is projected to grow at a compound annual growth rate of 4.9%, reaching approximately $163.3 million in 2032. While Ztalmy is currently the only approved drug, UCB recently announced positive topline results from its Phase 3 GEMZ study for Fintepla (fenfluramine) and is preparing to enter the market. Jazz Pharmaceuticals' Epidiolex (cannabidiol) is also prescribed off-label for patients with refractory epilepsy, capturing a portion of the market share, suggesting increased competition in the future. Marinus will need to overcome the challenges of negotiating pricing and establishing an independent distribution network in Europe to maintain its market leadership.